Company profile
FibroBiologics, Inc.
NASDAQ:FBLGBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07096934 | phase1_2 | recruiting | 2026-06-01 | 2026-12-31 | FibroBiologics | Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care |
| NCT05080270 | — | completed | 2020-09-21 | 2021-06-08 | FibroBiologics | Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis |
FDA applications (0)
No records yet.